Organon inks $103M deal for pertuzumab and denosumab biosimilars
Organon is looking to boost its biosimilar portfolio with two well-known brand copies in development by Shanghai-based Henlius Biotech.
The women’s health pharma is paying $73 million upfront, plus up to $30 million in 2022 milestone payments, for the pertuzumab biosimilar to Roche’s Genentech’s breast cancer drug Perjeta and the denosumab biosimilar to Amgen’s Prolia for osteoporosis and Xgeva for bone problem prevention in cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.